An interventional study of Postponement of antihypertensive treatment in Hypertension and Blood Pressure, High, sponsored by Annina Vischer. Status unknown at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Annina Vischer · Not applicable, Interventional, and Diagnostic
The goal of this clinical trial is to analyse the prevalence of new or uncontrolled arterial hypertension (AHT) after hospital discharge of medical in-patients with elevated blood pressure (BP) values during hospitalisation.
The main questions it aims to answer are:
Participants will either be treated according to their physicians' decision or antihypertensive treatment adaptions will be postponed until after hospital discharge.
6,834 studies on the registry are indexed under Hypertension; 971 are open to participants now.
This study's planned enrollment of 800 is above the median of 90 across 5,095 interventional studies indexed under Hypertension.
Browse Hypertension studies →This is the only study on the registry with Annina Vischer as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be treated according to their treating physicians' decision.
Antihypertensive treatment adaptions will be postponed until after a 24h ambulatory blood pressure measurement (ABPM) 4 weeks after hospital discharge.
Other: Postponement of antihypertensive treatment
Hypertensive blood pressure values in medical in-patients will not be treated during hospitalisation until confirmed by ABPM 4 weeks after hospital discharge
Prevalence of persisting new or uncontrolled arterial hypertension
Elevated blood pressure values in ambulatory blood pressure monitoring
Time frame: 4 weeks after hospital discharge
Prevalence of a combined hypertensive complication endpoint
Consisting of intracerebral bleeding, ischemic stroke, myocardial infarction, cardiovascular death or cardiovascular re-hospitalization
Time frame: Until 4 weeks after hospital discharge
Prevalence of a combined hypotensive complication endpoint
Consisting of falls, acute kidney injury, electrolyte disturbances, re-hospitalizations due to hypotension, or BP values on ABPM below the lower treatment limit
Time frame: Until 4 weeks after hospital discharge
Clinic blood pressure measurement in mmHg
Documented in the patient documentation
Time frame: At baseline
Research blood pressure measurement in mmHg
Standardized blood pressure measurement taken by research staff
Time frame: At baseline
Prevalence of previously unknown arterial hypertension
No previously documented diagnosis of arterial hypertension and no antihypertensive treatment
Time frame: At baseline
Prevalence of female gender
As reported by participant
Time frame: At baseline
Prevalence of re-hospitalization for any cause
According to hospital documentation and patient interrogation
Time frame: Until 4 weeks after hospital discharge
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Dec 2024, 13 months after the start.
Of 1,339 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 42. This study's planned 13 months is below that.
Counting every sponsor, half of 1,433 studies reached it within 23 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.